CoChat

Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy

Open access
Coleman, Michael P. · 2022 · Neurotherapeutics

The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.

Abstract

This review addresses the longstanding debate over whether amyotrophic lateral sclerosis (ALS) is a 'dying back' or 'dying forward' disorder in the light of new gene identifications and the increased understanding of mechanisms of action for previously identified ALS genes. While the topological pattern of pathology in animal models, and more anecdotally in patients is indeed 'dying back', this review discusses how this fits with the fact that many of the major initiating events are thought to occur within the soma. It also discusses how widely varying ALS risk factors, including some impacting axons directly, may combine to drive a common pathway involving TAR DNA binding protein 43 (TDP-43) and neuromuscular junction (NMJ) denervation. The emerging association between sterile alpha and TIR motif-containing 1 (SARM1), a protein so far mostly associated with axon degeneration, and sporadic ALS is another major theme. The strengths and limitations of the current evidence supporting an association are considered, along with ways in which SARM1 could become activated in ALS. The final section addresses SARM1-based therapies along with the prospects for targeting other axonal steps in ALS pathogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13311-022-01297-6

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Fully denervated NMJs in SOD1G93A transgenic mice. A complete motor unit in the sternomastoid muscle that lacks a single normal junction. More proximal parts of this intramuscular axon arbor appear substantially normal giving the characteristic ‘winter tree’ appearance. (Reproduced with permission from Schaefer et al. [18])
Fig. 1 Fully denervated NMJs in SOD1G93A transgenic mice. A complete motor unit in the sternomastoid muscle that lacks a single normal junction. More proximal parts of this intramuscular axon arbor appear substantially normal giving the characteristic ‘winter tree’ appearance. (Reproduced with permission from Schaefer et al. [18])CC BY · PubMed Central
Fig. 2 Soma and axonal deficits in ALS. Many of the most important causal steps in ALS are likely to take place in the soma but some are primarily axonal. ‘Dying back’ can result from a failure of the weakened soma to support its axon but this may be particularly reinforced when combined with additional problems in the axon
Fig. 2 Soma and axonal deficits in ALS. Many of the most important causal steps in ALS are likely to take place in the soma but some are primarily axonal. ‘Dying back’ can result from a failure of the weakened soma to support its axon but this may be particularly reinforced when combined with additional problems in the axonCC BY · PubMed Central
Fig. 3 The multiple triggers of programmed axon death in human disease. The NAD(P)ase and/or base exchange activity of SARM1 drives degeneration. It occurs in axons specifically when its upstream regulator, NMNAT2, falls below a threshold level, which may occur after axon injury, NMNAT2 LoF mutation or axonal transport deficits, such as caused by some cancer chemotherapeutics targeting microtubules. SARM1 can also be activated directly by GoF mutation or some toxins, and this can also cause death of the soma. Some viruses also cause SARM1-dependent degeneration
Fig. 3 The multiple triggers of programmed axon death in human disease. The NAD(P)ase and/or base exchange activity of SARM1 drives degeneration. It occurs in axons specifically when its upstream regulator, NMNAT2, falls below a threshold level, which may occur after axon injury, NMNAT2 LoF mutation or axonal transport deficits, such as caused by some cancer chemotherapeutics targeting microtubules. SARM1 can also be activated directly by GoF mutation or some toxins, and this can also cause death of the soma. Some viruses also cause SARM1-dependent degenerationCC BY · PubMed Central
Fig. 4 Age-related changes in motor unit size. A–D: Motor units from the omohyoid (A, B) and extraocular (C, D) muscles of young adult (A, C) and old (B, D) mice. E, F: Motor unit size in young adult and old omohyoid (E) and extraocular (F) muscles showing the increase in size specifically in the omohyoid motor units due to sprouting of surviving motor neurons. (Reproduced from Valdez et al. [83])
Fig. 4 Age-related changes in motor unit size. A–D: Motor units from the omohyoid (A, B) and extraocular (C, D) muscles of young adult (A, C) and old (B, D) mice. E, F: Motor unit size in young adult and old omohyoid (E) and extraocular (F) muscles showing the increase in size specifically in the omohyoid motor units due to sprouting of surviving motor neurons. (Reproduced from Valdez et al. [83])CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 122 references

Cited by

See all 33

Metadata

Authors
Coleman, M. P.
Affiliations
University of Cambridge (GB)
Corresponding author
Coleman, Michael P.
Venue
Neurotherapeutics
Publisher
Elsevier BV
Published
2022-07
Volume
19
Issue
4
Pages
1133-1144
ISSN
1878-7479 (ISSN-L)
OpenAlex
W4303453393
Cited by
33
References
121
Citations by year
2026: 6 · 2025: 12 · 2024: 10 · 2023: 4 · 2022: 1
FWCI
0.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Neurotherapeutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo
Funders
  • John and Lucille Van Geest Foundation
  • Robert Packard Center for ALS Research, Johns Hopkins University
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
amyotrophic lateral sclerosis, axonal degeneration, dying back, TDP-43, neuromuscular junction denervation, SARM1, axonopathy, ALS risk factors, ALS pathogenesis
MeSH terms
Amyotrophic Lateral Sclerosis, Animals, Axons, Biology, Cytoskeletal Proteins, DNA-Binding Proteins, Armadillo Domain Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy. https://app.cochat.ai/papers/10.1007/s13311-022-01297-6
The paper
Coleman, M. P. (2022). Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy. Neurotherapeutics. https://doi.org/10.1007/s13311-022-01297-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.